Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» SAGE Therapeutics
SAGE Therapeutics
10 key clinical trials to watch in the first half of 2021
10 key clinical trials to watch in the first half of 2021
BioPharma Dive
clinical trials
Novavax
AstraZeneca
JNJ
vaccines
COVID-19
Biomarin
Amgen
Merck
Pfizer
Roche
SAGE Therapeutics
Biogen
Vertex Pharmaceuticals
Flag link:
A Bright Day for Two Companies as New CEOs Announced
A Bright Day for Two Companies as New CEOs Announced
BioSpace
Pharma CEOs
SAGE Therapeutics
Samsung BioLogics
Flag link:
Is Biogen Getting Desperate?
Is Biogen Getting Desperate?
Motley Fool
Biogen
SAGE Therapeutics
major depressive disorder
depression
Flag link:
[video+transcript]Here's Why Biotech Deals Are All the Rage Right Now
[video+transcript]Here's Why Biotech Deals Are All the Rage Right Now
Motley Fool
biotech
M&A
Biogen
SAGE Therapeutics
Eli Lilly
Precision Biosciences
Merck
OncoImmune
Flag link:
Biogen bets $1.5B on Sage's once-failed depression drug
Biogen bets $1.5B on Sage's once-failed depression drug
Fierce Biotech
Biogen
SAGE Therapeutics
zuranolone
depression
Flag link:
Biogen stocks up on Sage's brain drugs in $3B deal
Biogen stocks up on Sage's brain drugs in $3B deal
BioPharma Dive
Biogen
SAGE Therapeutics
brain diseases
Flag link:
Sage shares data on retreatment with depression drug zuranolone
Sage shares data on retreatment with depression drug zuranolone
Fierce Biotech
SAGE Therapeutics
zuranolone
clinical trials
major depressive disorder
Flag link:
Is There Any Hope Left for Sage Therapeutics?
Is There Any Hope Left for Sage Therapeutics?
Motley Fool
SAGE Therapeutics
SAGE-217
SAGE-324
Flag link:
Sage to lay off half of workforce in cost-cutting retrenchment
Sage to lay off half of workforce in cost-cutting retrenchment
BioPharma Dive
SAGE Therapeutics
layoffs
depression
Zulresso
Flag link:
Sage to run 3 new studies to save once-failed depression drug
Sage to run 3 new studies to save once-failed depression drug
Fierce Biotech
SAGE Therapeutics
SAGE-217
major depressive disorder
clinical trials
Flag link:
Sage rethinks SAGE-217 program after phase 3 failure
Sage rethinks SAGE-217 program after phase 3 failure
Fierce Biotech
SAGE Therapeutics
clinical trials
depression
SAGE-217
Flag link:
Here's Why Sage Therapeutics Lost 53.3% in December
Here's Why Sage Therapeutics Lost 53.3% in December
Motley Fool
SAGE Therapeutics
SAGE-217
major depressive disorder
clinical trials
Flag link:
Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60%
Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60%
Xconomy
SAGE Therapeutics
clinical trials
SAGE-217
major depressive disorder
Flag link:
Sage's new drug starts slow, as Wall Street waits for depression data
Sage's new drug starts slow, as Wall Street waits for depression data
Biopharma Dive
SAGE Therapeutics
postpartum depression
Zulresso
drug launches
Flag link:
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
Yahoo/Zacks.com
earnings
biotech
Eyenovia
SAGE Therapeutics
AC Immune
Ascendis
NGM Biopharmaceuticals
Flag link:
Upcoming events – Sage targets depression and Biogen aims for lupus
Upcoming events – Sage targets depression and Biogen aims for lupus
EP Vantage
SAGE Therapeutics
SAGE-217
major depressive disorder
Biogen
BIIB059
lupus
Flag link:
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression
BioSpace
SAGE Therapeutics
treatment-resistant depression
SAGE-217
Flag link:
Marinus leaves the way clear for Sage
Marinus leaves the way clear for Sage
EP Vantage
Marinus Pharma
SAGE Therapeutics
ganaxolone
clinical trials
postpartum depression
Flag link:
Sage strategy for postpartum depression drug Zulresso keys on patient support
Sage strategy for postpartum depression drug Zulresso keys on patient support
Fierce Pharma
SAGE Therapeutics
postpartum depression
patients
Zulresso
Flag link:
2 Biotech Takeout Targets Perfect for Biogen
2 Biotech Takeout Targets Perfect for Biogen
Motley Fool
Biogen
M&A
SAGE Therapeutics
Neurocrine Biosciences
Flag link:
Pages
1
2
3
4
next ›
last »